Insider · CIK 0002022087
David Bredt
Files at RAPP (Rapport Therapeutics, Inc.). First filing Mar 17, 2025, latest Feb 19, 2026.
In brief
David Bredt files SEC Form 4 as officer at RAPP (Rapport Therapeutics, Inc.). Since Mar 17, 2025, David Bredt has reported 0 open-market buys worth $0 and 13 open-market sells worth $2.2M, the latest filed on Feb 19, 2026.
A track record needs three past buys with six months of prices behind them; David Bredt has 0, so none is measured yet.
The newest scored trade: sold $247k of RAPP on Feb 17, 2026, filed Feb 19, 2026, scored 1 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 6 sells worth $1.4M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RAPP: Rapport Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 1Weak | Rapport Therapeutics, Inc. | $247k 8,500 shares | -2% | +306% from low-9% from high | |
| 16Weak | Rapport Therapeutics, Inc. | $228k 8,500 shares | -2% | +276% from low-16% from high | |
| 42Moderate | Rapport Therapeutics, Inc. | $197k 6,567 shares | -2% | +324% from low-5% from high | |
| 16Weak | Rapport Therapeutics, Inc. | $255k 8,500 shares | -2% | +314% from low-6% from high | |
| 22Weak | Rapport Therapeutics, Inc. | $214k 8,500 shares | -2% | +251% from low-20% from high | |
| 15Weak | Rapport Therapeutics, Inc. | $219k 8,500 shares | -2% | +261% from low-18% from high | |
| 22Weak | Rapport Therapeutics, Inc. | $206k 8,500 shares | -2% | +246% from low-21% from high | |
| 6Weak | Rapport Therapeutics, Inc. | $127k 8,500 shares | -2% | +106% from low-50% from high | |
| 5Weak | Rapport Therapeutics, Inc. | $119k 8,500 shares | -2% | +101% from low-51% from high | |
| 5Weak | Rapport Therapeutics, Inc. | $94k 8,500 shares | -2% | +57% from low-62% from high | |
| 4Weak | Rapport Therapeutics, Inc. | $81k 8,500 shares | -2% | +36% from low-67% from high | |
| 4Weak | Rapport Therapeutics, Inc. | $81k 8,500 shares | -2% | +34% from low-67% from high | |
| 4Weak | Rapport Therapeutics, Inc. | $92k 8,500 shares | -2% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 15, 2026 | RAPP RAPPORT THERAPEUTICS INC | 17,000 0.04% of outstanding | $466k | Jan 15, 2026 | $667k |
| Jan 2, 2026 | RAPP Rapport Therapeutics, Inc. | 6,567 0.01% of outstanding | $197k | Jan 2, 2026 | $688k |
| Oct 15, 2025 | RAPP Rapport Therapeutics, Inc. | 25,500 0.07% of outstanding | $634k | Oct 15, 2025 | $333k |
| Jun 16, 2025 | RAPP Rapport Therapeutics, Inc. | 34,000 0.09% of outstanding | $380k | Jun 16, 2025 | $163k |
| Mar 14, 2025 | RAPP RAPPORT THERAPEUTICS, INC. | 25,500 0.07% of outstanding | $256k | Mar 14, 2025 | none |
Transactions
Every row this insider has filed, 27 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -900 | $28.02 | $25k | 394,675 | Feb 19, 2026 |
| Feb 17, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,400 | $28.95 | $156k | 389,275 | Feb 19, 2026 |
| Feb 17, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,200 | $29.59 | $65k | 387,075 | Feb 19, 2026 |
| Feb 19, 2026 | RAPP Rapport Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +6,000 | $1.80 | $11k | 393,075 | Feb 19, 2026 |
| Feb 19, 2026 | RAPP Rapport Therapeutics, Inc. | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 88,080 | Feb 19, 2026 |
| Feb 2, 2026 | RAPP Rapport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +103,000 | $0.00 | $0 | 103,000 | Feb 4, 2026 |
| Jan 15, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,300 | $26.83 | $223k | 395,775 | Jan 16, 2026 |
| Jan 15, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -200 | $27.40 | $5,480 | 395,575 | Jan 16, 2026 |
| Dec 31, 2025 | RAPP Rapport Therapeutics, Inc. | AGrant or award Common Stock | -18,000 | - | - | 410,642 | Jan 5, 2026 |
| Dec 31, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock | -6,567 | $30.05 | $197k | 404,075 | Jan 5, 2026 |
| Dec 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,704 | $29.95 | $231k | 393,438 | Dec 16, 2025 |
| Dec 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -796 | $30.68 | $24k | 392,642 | Dec 16, 2025 |
| Nov 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,156 | $24.84 | $78k | 406,486 | Nov 18, 2025 |
| Nov 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,344 | $25.39 | $136k | 401,142 | Nov 18, 2025 |
| Oct 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,418 | $25.73 | $191k | 410,724 | Oct 16, 2025 |
| Oct 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,082 | $26.16 | $28k | 409,642 | Oct 16, 2025 |
| Sep 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,098 | $23.88 | $122k | 421,544 | Sep 17, 2025 |
| Sep 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,402 | $24.66 | $84k | 418,142 | Sep 17, 2025 |
| Aug 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,300 | $14.98 | $124k | 426,842 | Aug 18, 2025 |
| Aug 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -200 | $15.79 | $3,158 | 426,642 | Aug 18, 2025 |
| Jul 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,500 | $14.00 | $119k | 435,142 | Jul 16, 2025 |
| Jun 16, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,500 | $11.00 | $94k | 443,642 | Jun 18, 2025 |
| May 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,500 | $9.56 | $81k | 452,142 | May 19, 2025 |
| Apr 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,500 | $9.57 | $81k | 460,642 | Apr 16, 2025 |
| Mar 14, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,500 | $10.85 | $92k | 469,142 | Mar 17, 2025 |
| Feb 3, 2025 | RAPP Rapport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 4, 2025 |
| Jun 6, 2024 | RAPP Rapport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +28,302 | $0.00 | $0 | 28,302 | Jun 10, 2024 |
Questions about David Bredt
Answered from the filings on this page, as of the latest one.
Is David Bredt buying or selling?
In the last 12 months David Bredt reported 0 open-market buys worth $0 and 6 open-market sells worth $1.4M on SEC Form 4; the latest was sold $247k of RAPP on Feb 17, 2026. Grants, option exercises and tax withholding are not counted.
How did David Bredt's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Bredt has 0.
Where does David Bredt file Form 4?
David Bredt has filed Form 4 at RAPP (Rapport Therapeutics, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.